Vidac wins renewed “Buy” rating as Phase 2 AK trial gets green light in Germany -analysts see major upside ahead.

Vidac Pharma Holding Plc. (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ)

Their continued confidence highlights the clear direction of our program as we move toward a Phase 3 trial”
— Dr. Max Herzberg

LONDON, UNITED KINGDOM, November 21, 2025 /EINPresswire.com/ -- Vidac Pharma Holdings Plc., a clinical-stage oncology company pioneering first-in-class therapies targeting the unique metabolism of cancer cells, is pleased to announce that Sphene Capital, the highly respected European independent analyst house, has once again issued a “Buy” recommendation for Vidac Pharma’s shares. The reaffirmed rating comes with no change in the analyst’s GBP-based valuation of the Company. The target price has been adjusted slightly from €4.20 to €4.10 per share, reflecting currency movements between the British Pound and Euro, while maintaining confidence in the Company’s long-term value.

This renewed “Buy” recommendation follows the recent regulatory authorization in Germany to initiate Vidac Pharma’s new Phase 2 clinical study in actinic keratosis (AK), focusing specifically on highly proliferative lesions—a clinically significant patient segment with considerable unmet need.

Dr. Max Herzberg, Founder and CEO of Vidac Pharma, commented:
“We are proud that a high-quality analyst group such as Sphene Capital, through their understanding of our science, recognizes the importance of this new claim for our future market positioning. Their continued confidence highlights the clear direction of our program as we move toward a Phase 3 trial.”

Vidac Pharma remains committed to advancing its innovative Tuvatexib (VDA-1102) platform as it continues to develop first-in-class therapies addressing the abnormal metabolic pathways of cancer and pre-cancerous skin lesions.
To read the complete Sphene Capital analysis, please click the link https://vidacpharma.com/en/investor-relations

Max Herzberg
Vidac pharma Holding Plc
+972 54-425-7381
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]